FGSAX
Price
$61.28
Change
-$0.44 (-0.71%)
Updated
Jul 2 closing price
Net Assets
6.8B
JDMAX
Price
$144.50
Change
-$0.05 (-0.03%)
Updated
Jul 2 closing price
Net Assets
22.28B
Interact to see
Advertisement

FGSAX vs JDMAX

FGSAX vs JDMAX Comparison Chart in %
View a ticker or compare two or three
VS
FGSAX vs. JDMAX commentary
Jul 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGSAX is a Buy and JDMAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JDMAX has more cash in the bank: 22.3B vs. FGSAX (6.8B). FGSAX (0.00) and JDMAX (0.00) have matching dividends . FGSAX was incepted earlier than JDMAX: FGSAX (42 years) vs JDMAX (17 years). FGSAX (1.30) is less costly to investors than JDMAX (1.14). FGSAX is a more actively managed with annual turnover of: 78.00 vs. JDMAX (17.00). JDMAX (6%) and FGSAX (6%) have equivalent initial investment costs. FGSAX has a lower initial minimum investment than JDMAX: FGSAX (1500) vs JDMAX (2500). JDMAX annual gain was more profitable for investors over the last year : 4.20 vs. FGSAX (-3.31). FGSAX return over 5 years is better than : 8.50 vs. JDMAX (-13.82).
FGSAXJDMAXFGSAX / JDMAX
Total Expense Ratio1.151.14101%
Annual Report Gross Expense Ratio1.301.14114%
Fund Existence42 years17 years-
Gain YTD1.6258.64719%
Front Load6%6%96%
Min. Initial Investment1500250060%
Min. Initial Investment IRAN/AN/A-
Net Assets6.8B22.3B30%
Annual Yield % from dividends0.000.00-
Returns for 1 year-3.314.20-79%
Returns for 3 years49.1712.77385%
Returns for 5 years8.50-13.82-62%
Returns for 10 years92.5462.75147%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NFLX77.653.46
+4.66%
Netflix Inc.
KPLT7.610.31
+4.25%
Katapult Holdings
WBTN11.640.23
+2.02%
Webtoon Entertainment Inc.
KEX129.84-1.13
-0.86%
Kirby Corp
CION6.39-0.12
-1.84%
CION Investment Corp